PAVmed Inc. (PAVM)
Nasdaq · Healthcare · Medical Devices
$2.66−7.32%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $21.3M
- 52-week range
- $2.61 – $28.44
- 52-week change
- −78.74%
- EPS (trailing)
- −$14.20
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $71K (−97.63%)
- Net income
- −$3.8M
- Operating margin
- −30712.7%
- Diluted EPS
- −$5.63
- Free cash flow
- −$5.2M
From the company’s annual report on SEC EDGAR.
About PAVmed Inc.
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Headquarters: New York, United States · 41 employees · pavmed.com